p-SCN-Bn-TCMC HCl | CAS#2780352-89-6 (HCl) | radiolabel conjugate

MedKoo Cat#: 620115 | Name: p-SCN-Bn-TCMC HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

p-SCN-Bn-TCMC is a bifunctional chelator, which contains a reactive tioisocyante linker and powerful chelator TCMC. The thioisocynate functional group is reactive to amino and hydroxy groups, and can be used to make conjugate with peptides, antibodies and other bio-macro-molecules. TCMC is a powerful chelator with capability to strongly bind radio-isotopic heavy metal ion, which are widely used for radio-diagnostic/imaging research.

Chemical Structure

p-SCN-Bn-TCMC HCl

CAS#2780352-89-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 620115

Name: p-SCN-Bn-TCMC HCl

CAS#: 2780352-89-6 (HCl)

Chemical Formula: C24H41Cl4N9O4S

Exact Mass: 0.0000

Molecular Weight: 693.51

Elemental Analysis: C, 41.57; H, 5.96; Cl, 20.45; N, 18.18; O, 9.23; S, 4.62

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 850.00	2 Weeks
100mg	USD 1,550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

282097-63-6 (free base) 2153478-57-8 (HCl) 2780352-89-6 (HCl)

Synonym

p-SCN-Bn-TCMC; p-SCN-Bn-TCMC HCl; p-SCN-Bn-TCMC hydrochloride,

IUPAC/Chemical Name

2-[(4-Isothiocyanatophenyl)methyl]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide tetrahydrochloride

InChi Key

AWINXKJPBPFQMY-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H37N9O4S.4ClH/c25-21(34)13-30-5-6-31(14-22(26)35)9-10-33(16-24(28)37)20(12-32(8-7-30)15-23(27)36)11-18-1-3-19(4-2-18)29-17-38;;;;/h1-4,20H,5-16H2,(H2,25,34)(H2,26,35)(H2,27,36)(H2,28,37);4*1H

SMILES Code

O=C(N)CN1C(CC2=CC=C(N=C=S)C=C2)CN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CC1.[H]Cl.[H]Cl.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 693.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Westrøm S, Generalov R, Bønsdorff TB, Larsen RH. Preparation of (212)Pb-labeled monoclonal antibody using a novel (224)Ra-based generator solution. Nucl Med Biol. 2017 Aug;51:1-9. doi: 10.1016/j.nucmedbio.2017.04.005. Epub 2017 Apr 26. PubMed PMID: 28486098. 2: Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM. Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2016 Nov 30. [Epub ahead of print] PubMed PMID: 27906723; PubMed Central PMCID: PMC5449266. 3: Kasten BB, Azure MT, Schoeb TR, Fisher DR, Zinn KR. Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primates. Nucl Med Biol. 2016 Jul;43(7):391-6. doi: 10.1016/j.nucmedbio.2016.04.001. Epub 2016 Apr 13. PubMed PMID: 27179247. 4: Yong K, Brechbiel M. Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Med Sci. 2015;2(3):228-245. Epub 2015 Aug 18. PubMed PMID: 26858987; PubMed Central PMCID: PMC4743765. 5: Milenic DE, Molinolo AA, Solivella MS, Banaga E, Torgue J, Besnainou S, Brechbiel MW, Baidoo KE. Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial. Pharmaceuticals (Basel). 2015 Jul 24;8(3):416-34. doi: 10.3390/ph8030416. PubMed PMID: 26213947; PubMed Central PMCID: PMC4588175. 6: Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000 Jan;27(1):93-100. PubMed PMID: 10755652. Randhawa P, Carbo-Bague I, Davey PRWJ, Chen S, Merkens H, Uribe CF, Zhang C, Tosato M, Bénard F, Radchenko V, Ramogida CF. Exploration of commercial cyclen-based chelators for mercury-197 m/g incorporation into theranostic radiopharmaceuticals. Front Chem. 2024 Feb 8;12:1292566. doi: 10.3389/fchem.2024.1292566. PMID: 38389726; PMCID: PMC10881723. Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland ØS, Juzeniene A. Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer. Int J Mol Sci. 2021 May 1;22(9):4815. doi: 10.3390/ijms22094815. PMID: 34062920; PMCID: PMC8124365. Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer. J Labelled Comp Radiopharm. 2020 Mar;63(3):129-143. doi: 10.1002/jlcr.3825. Epub 2020 Jan 29. PMID: 31919866. Dos Santos JC, Schäfer M, Bauder-Wüst U, Lehnert W, Leotta K, Morgenstern A, Kopka K, Haberkorn U, Mier W, Kratochwil C. Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019 May;46(5):1081-1091. doi: 10.1007/s00259-018-4220-z. Epub 2019 Jan 3. PMID: 30603987; PMCID: PMC6451745.